Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Jagannathan, 2020 NCT04331899

peginterferon (n=60) vs. placebo (n=60)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Peginterferon Lambda-1a
Peginterferon Lambda-1a (180 mcg subcutaneous injection) single dose alone with standard of care.

Control treatment

Placebo
Normal saline placebo subcutaneous injection along with standard of care Treatment for COVID-19 Infection.

Patients

COVID-19 mild to moderate

Age ≥ 18 years and ≤ 75 years at the time of the assessmentAble and willing to understand the study, adhere to all study procedures, and provide written informed consentDiagnosis of COVID-19 disease:If symptomatic, the presence of mild to moderate symptoms without signs of respiratory distress, with FDA-cleared molecular diagnostic assay positive for SARS-CoV-2 within 72 hours from swab to the time of commencing informed consent:If asymptomatic, initial diagnosis of SARS-CoV-2 infection with positive FDA-cleared molecular diagnostic assay obtained no more than 72 hours from initial swab to the time of commencing informed consent

Method

Open-label.

Single-blind.

Phase II. Single-blind study in which only patients are blinded.

Remark